Novo Nordisk Gets US Approval for Wegovy Obesity Pill
Photographer: Dhiraj Singh/Bloomberg
Good morning. Novo Nordisk gets a head start over rival Eli Lilly. The year-end markets rally continues. Hear what some of Britain’s bosses have to say about 2026. Listen to the day’s top stories.